72 results about "Plga nanoparticles" patented technology

A composition and an associated method for hepatic targeted delivery of thyroid receptor beta1 (TRβ1) agonist to a liver of a subject. The composition includes hydrophobic nanoparticles, a liver targeting moiety exterior to each nanoparticle and covalently bonded to each nanoparticle, and at least one TRβ1 agonist encapsulated within each nanoparticle. The nanoparticles include chitosan hybrid nanoparticles, amine-modified PLGA nanoparticles, solid lipid nanoparticles, and combinations thereof. The liver targeting moiety includes Glycyrrhetinic acid (GA), Lactobionic acid (LA), or combinations thereof.

The present invention includes compositions and methods of making an activated polymeric nanoparticle for targeted drug delivery that includes a biocompatible polymer and an amphiphilic stabilizing agent non-covalently associated with a spacer compound that includes at least one electrophile that selectively reacts with any nucleophilic on a targeting agent and places the targeting agent on the exterior surface of a biodegradable nanoshell, wherein an active agent is loaded with the nanoshell.

The invention provides a tumor active-targeting nano drug delivery system capable of reversing drug-resistance. The drug delivery system is polylactic-co-glycolic acid (PLGA) nanoparticles mixed with lipid, and the nanoparticle core is PLGA. Drug-loaded nanoparticles are prepared as follows: inserting AA-polyethylene glycol-cholesterol linkers and triphenylphosphine-cholesterol linkers in the surface of PLGA; encapsulating DOX into the PLGA nanoparticles mixed with lipid to obtain the drug-loaded nanoparticles. The drug delivery system has the acid sensitivity, which enables the drug delivery system to proactively recognize tumor cells and position and release DOX into the mitochondria and cell nuclei of tumor cells, thereby enhancing the anti-tumor activity, reversing the drug-resistance of the tumor and providing a new strategy for improving the efficacy of DOX.

The invention relates to the technical field of medical plastic surgery, in particular to the technical field of facial filling and anti-wrinkle, in particular, it is an injection filling cosmetic modification anti-aging, skin beautification and facial rejuvenation material. The preparation formula of the present invention includes hyaluronic acid, collagen, vitamin E and PLGA. The preparation method comprises: 1) preparing high-viscosity gel; 2) preparing PLGA nano-microspheres; 3) fully mixing high-viscosity gel and PLGA nano-microspheres; 4) sterilizing and filling. Compared with the prior art, the present invention has the beneficial effect that: the combined use of collagen and hyaluronic acid reduces skin erythema, swelling, hardening or itching, muscle pain, urticaria or Other symptoms such as rash. It reduces the probability of severe complications such as peripheral blood circulation embolism, skin necrosis, retinal artery embolism, and cardiocerebral artery embolism that may be caused by simple hyaluronic acid injection, and the safety of product use is improved.

The invention relates to the fields of medicines and medical instruments, and particularly relates to a preparation method for a gel scaffold for repairing articular cartilage injuries. The preparation method specifically comprises the following steps: (1) modifying sodium hyaluronate; (2) dissolving PLGA nano-particles of a controlled-release small molecular compound in the sodium hyaluronate modified in the step (1), and then adding with a photoinitiator to obtain a controlled-release small molecular compound-sodium hyaluronate gel compound system; and (3) injecting/filling the controlled-release small molecular compound-sodium hyaluronate gel compound system to the articular cartilage injuries to be repaired for being irradiated by an ultraviolet point light source, so as to obtain the gel scaffold for repairing articular cartilage injuries. The gel scaffold provided by the invention is high in plasticity, and capable of being randomly shaped according to the shapes of cartilage defects; harmful substances are not introduced in the whole process, and the gel scaffold can be used in vivo.

A polylactic PLA or poly-cyclic diester lactide PLGA nanometer particle for coating plant extract and its production are disclosed. PLA or PLGA nanometer particle is characterized by: coating plant extract as core matter with PLA or PLGA as shell membrane and forming nanometer spherical particle matter. The production is carried out by taking PLA or PLGA with good biological compatibility as carrier, taking polyvinyl alcohol PVA as emulsifier, and adopting solvent evolution method. Its advantages include low cost, simple process, to improve water soluble ability of main components, to improve plant extract adsorptive rate and biological utilizing rate.

The invention belongs to the technical field of pharmacy and particularly relates to an erythrocyte membrane-encapsulated tetrandrine PLGA nanoparticle and a preparation method and application thereof. The nanoparticle structurally includes an erythrocyte membrane, PLGA and tetrandrine, the tetrandrine is combined with PLGA to form a tetrandrine-PLGA nanocore, and the erythrocyte membrane is encapsulated outside the tetrandrine-PLGA nanocore. The preparation method is simple and efficient. The nano preparation improves the biocompatibility of a whole drug delivery system, long circulation andsustained release of the tetrandrine in the human body are achieved, toxic and side effects caused by too high blood medicine peak concentration of common injections are avoided, and the nanoparticlehas a good application prospect.

The invention provides TA-Fe (III) modified PLGA nanoparticles coating doxorubicin hydrochloride and a preparation method thereof. The mPEG-PLGA is selected as a carrier material, TA and Fe (III) are used as modification materials, and the nanoparticles are prepared by combination of a multiple emulsion-solvent volatilization method and coordination modification of the TA and Fe (III). The encapsulation efficiency of the nanoparticles is 80.14+/-9.79%, and the drug loading is 0.85+/-0.08%. The particle size of the nanoparticles is 146.9+/-14.3 nm, the Zeta potential is -21.0+/-0.2 mV, and the polydispersity index is 0.214+/-0.113. The surfaces of the nanoparticles obtained by the preparation method are smooth and round without adhesion, and the nanoparticles have controllable size, small particle size and narrow range of particle size, are convenient for intravenous injection, and have good sustained release effect. The TA-Fe (III) modified nanoparticles have a good drug encapsulation effect, can significantly reduce drug burst release and have a pH responsiveness effect. Therefore, the nanoparticles have broader application prospects in targeted delivery as an anti-tumor drug.

The invention relates to nimodipine/ligustrazine double-load PLGA nanoparticles which are prepared through a method comprising the steps that: nimodipine, ligustrazine phosphate and a polylactic acid-glycolic acid copolymer are precisely weight according to a mass ratio of 1:5-20:40-60; the materials are dissolved into acetone, such that an organic phase is obtained; a PVA water solution with a mass concentration of 0.5-1.0% is adopted as an aqueous phase; under stirring, the organic phase is slowly dropped into the aqueous phase; when dropping is finished, the mixture is continued to be stirred for 2-4h under a constant temperature of 40-50 DEG C, such that the organic solvent is volatilized; centrifugation is carried out; a sediment is washed 2-3 timed by using distilled water, and is lyophilized, such that the nimodipine/ligustrazine double-loading PLGA nanoparticles are obtained. According to the invention, PLGA is adopted as a carrier material, and P-gp inhibitors TMP and NMD are applied in combination, such that NMD/TMP-PLGA-NPs are prepared. Therefore, defects of short drug half-life, easy generation of cytotoxicity, and the like of simple combination are avoided, a P-gp efflux effect is inhibited, and NMD distribution to tissues is promoted. Therefore, the nanoparticles have certain advantages over single-load nanoparticles.

The invention relates to daidzein-entrapped polylactic polyglycolic acid (PLGA) nanoparticles and a preparation method thereof in the technical field of nanomedicines. The nanoparticles comprise the following components in percentage by mass: 0.1 to 45 percent of daidzein, 25 to 95 percent of polylactic polyglycolic acid and 1 to 65 percent of pharmaceutic adjuvant, wherein the molecular weight of the PLGA is between 8,000 and 15,000, the polylactic polyglycolic acid is long-chain macromolecules in which the ratio of the lactic acid to glycollic acid is 50:50, and the pharmaceutic adjuvant is lecithin, cyclodextrin or polyvinyl alcohol (PVA). The daidzein-entrapped PLGA nanoparticles have the particle size of between 280 and 330 nanometers and concentrated particle size distribution, redissolved freeze-dried powder is not adhered, and the medicine loading rate of the PLGA nanoparticles is between 1 and 2 percent, and the encapsulating rate is between 80 and 84 percent.

Provided herein are terpenoid- and cannabinoid-encapsulating PLGA nanoparticles and pharmaceutical compositions comprising the nanoparticles. Further provided are methods of making and using the terpenoid- and cannabinoid-encapsulating PLGA nanoparticles for therapeutic purposes.

The invention discloses a ginsenoside Rg3 slow release nanometer microsphere composition, and a preparation method and a use thereof. The method is characterized in that a medicine coating matrix is a polylactic acid-glycolic acid copolymer (PLGA), polyvinyl alcohol (PVA) is adopted as an emulsifier, and Rg3-PLGA nanoparticles with good re-dispersibility are prepared through purifying and drying by adopting a solvent volatility technology; and the Rg3-PLGA nanoparticles are dried to form white powder which can be preserved for a long term. The particles have the advantages of smooth and round surfaces, no adhesion among the particles, good dispersiveness and uniform size, and the average particle size of the particles is 97.5 nm. The composition has high endophilicity to the PLGA material, has a high entrapment rate (of 94.3%), and has a good slow release performance, and the slow release period is 4 d or more. The nanoparticles can be used in antitumor therapy in an intravenous injection and local administration mode, and has wide application prospect.

Nanoparticulate compositions are disclosed. The nanoparticulate compositions typically include at least one, preferably two or more, active agent(s), one of which is an immunomodulatory compound, loaded into, attached to the surface of and/or enclosed within a delivery vehicle. The delivery vehicles can be nanolipogels including a polymeric core and a lipid shell or a biodegradable polymeric nanoparticle such as a PLGA nanoparticle. Typically, at least one of the active agents is an immunomodulator that increases an immune stimulatory response or decreases an immune suppressive response. In some embodiments, the particle includes both an immunomodulator that increases an immune stimulatory response and an immunomodulator that decreases an immune suppressive response. The particles can be decorated with a targeting moiety that improves delivery to a target cell. Methods of using the compositions to enhance an immune response and treat diseases such as cancer are also disclosed.

The invention relates to targeted multifunctional nanoparticles and a preparation method and application thereof, and belongs to the technical field of biological medicines. The targeted multifunctional nanoparticles are prepared by an ultrasonic double-emulsification method, covalent binding is carried out by branching PEI and PLGA, PLGA nanoparticles which have negative charge originally are modified into kation nanoparticles with positive charge, plasmids can be adsorbed effectively, it ensures that the plasmid cannot drop due to physical effect in a circulation system, and after the plasmid enters cells, the possibility that the plasmid is degraded by endoenzyme is also reduced. The nanoparticles further contain IR780 which can target tumor cell mitochondria, meanwhile, by strong fluorescent light and photosensitizer characteristics of IR780, the nanoparticles become a great fluorescent and photoacoustic imaging medium, and thus, tumors can be convenient to observe. The nanoparticles can carry drug to facilitate combination with transgenic therapy, tumor cells are killed favorably, and furthermore, toxic and side effects of chemotherapy drugs can further be reduced. The preparation method of the targeted multifunctional nanoparticles is simple, is easy to operate, and is suitable for expanded production.

The invention discloses a method for preparing a biological nanopatch constructed by astragaloside induced BMSC compound polylactic acid-glycolic acid nano-particle modified small intestinal submucosa matrix. The method comprises the following steps: preparing polylactic acid-glycolic acid nano-particles (PLGA) by adopting a multiple emulsion method; preparing a small intestinal submucosa matrix (SIS) having a natural three-dimensional ultra micro-structure by adopting a decellation technology to adsorb the PLGA nano-particles on the surface of SIS and favor adsorption and growth of host cells by means of the SIS after PLGA nano-particle surface modification; inducing BMSC by astragaloside to promote proliferation and differentiation of BMSC and enable the BMSC to compound and grow on the PLGA nano-particle surface modified small intestinal submucosa matrix (PLGA-SIS) of pigs. Therefore, the AS-BMSC-PLGA-SIS biological patch has stable physicochemical property, good biocompatibility and high mechanical strength, and is beneficial to tissue regeneration.

The invention provides cationic nanoparticles. The preparation method includes the following steps that 1, octadecylamine is dissolved in an organic solvent, so that the concentration of the octadecylamine is 0.4-1 mg/mL; 2, a PLGA is dissolved in the solution obtained in the step 1, so that the concentration of the PLGA is 10-40 mg/mL; 3, the F68 water solution having the concentration of 0.1-1% is taken and mixed with the solution obtained in the step 2, then ultrasonic treatment is performed to obtain an emulsification solution containing PLGA nanoparticles; 4, the cationic nanoparticle are obtained through emulsifying evaporation treatment. The preparation method is simple and easy to operate, the prepared product does not contain drugs, bactericidal and antibacterial effects are achieved only by utilizing the characteristics of the nanoparticles, an antibacterial action is strong, irritation is small, the cationic nanoparticles are prepared into mouth wash and have good biocompatibility with teeth, and the phenomenon that chromatosis and furthertooth color is changed is not likely to occur.

The invention relates to nanoparticle enhanced type hydrogel as well as a preparation method and application thereof. The nanoparticle enhanced type hydrogel is prepared by a preparation method comprising the following steps: S1, preparing sodium alginate modified PLGA (Poly(lactic-co-glycolic acid)) nanoparticles; S2: preparing a sodium alginate water solution; adding the PLGA nanoparticles obtained by S1; then adding a graphene oxide suspension solution into the mixed solution; uniformly stirring to obtain a mixed solution for later use; S3: preparing a gluconolactone water solution and adding the gluconolactone water solution into a mixed solution obtained by S2; slightly stirring and placing for some time, so as to obtain the nanoparticle enhanced type hydrogel. According to the nanoparticle enhanced type hydrogel, a nanoparticle surface group and calcium ions are specifically combined and an electrostatic action force between the nanoparticles is adopted, so that a new network isformed in a hydrogel network, and the mechanical property of the hydrogel is enhanced to the greatest extent. Materials of the hydrogel provided by the invention have good biocompatibility and no toxin on organisms; the preparation method is simple and low in cost and does not need large-size equipment; the preparation method has relatively great popularization and application value.

The invention provides an ultrasonic administration microbubble compound carrying an anti-tumor drug as well as a preparation method and application of the ultrasonic administration microbubble compound. The compound is prepared by connection of cationic microbubbles and an anti-tumor drug-PLGA nanoparticles through attraction of positive and negative charges. According to the preparation method, the GA-PLGA nano-particles are prepared by utilizing an ultrasonic emulsification effect, and the CMB and the GA-PLGA nano-particles are connected through charge attraction to form the CMBS-GA-PLGA micro-bubble compound due to the fact that the cationic micro-bubbles carry positive charges and the GA-PLGA nano-particles carry negative charges. The micro-bubbles generate a series of alternative changes such as expansion, shrinkage, oscillation and implosion under the effect of ultrasound, so that the permeability of a cell membrane is improved, the phenomenon is called as 'sound pore effect', gambogic acid can better act on glioblastoma cells by utilizing the 'sound pore effect' of the micro-bubbles under the action of ultrasound, and a new thought is expected to be provided for treatment of glioma.

The present disclosure provides a delivery system for controlled protein release without encapsulation. Identical, burst-free, extended release profiles for three different protein therapeutics were obtained with and without encapsulation in PLGA nanoparticles embedded within a hydrogel. Using both positively and negatively charged proteins, it was shown that short-range electrostatic interactions between the proteins and the PLGA nanoparticles are the underlying mechanism for controlled release. Moreover, tunable release was demonstrated by modifying nanoparticle concentration, nanoparticle size, or environmental pH. Additionally, the utility of this system was demonstrated in vivo for BDNF delivery in a rat model of stroke. These new insights obviate the need for encapsulation and offer promising, translatable strategies for more effective delivery of therapeutic biomolecules.

The invention discloses a targeting PLGA (poly(lactic-co-glycolic acid)) fluorescence probe coated with methylene blue, wherein, the targeting PLGA fluorescence probe uses methylene blue as a core and PLGA as a shell membrane, and PLGA is cross-linked with folic acid molecules through 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimides; the targeting PLGA fluorescence probe is targeting PLGA nanoparticles coated with methylene blue; and PLGA has good biocompatibility and biodegradability and can be discharged out of body though normal physiological pathways. Light stability of methylene blue is enhanced after methylene is coated on PLGA; at the same time, the particles crosslinked with folic acid can recognize tumors in vivo, has low preparation cost and is convenient in operation and popularization.

The invention relates to the field of nano medicine and biological detoxification, in particular to a cyclic gamma-polyglutamic acid modified poly-N-isopropylacrylamide hydrogel loaded nano sponge detoxification system and a preparation method thereof. PLGA nanoparticles are wrapped with erythrocyte membrane vesicae prepared from extracted erythrocyte membranes to prepare nano sponge, and cyclic gamma-polyglutamic acid modified poly-N-isopropylacrylamide hydrogel is loaded with the nano sponge to obtain the system. The prepared hydrogel of a three-dimensional network structure has good biocompatibility, can be loaded with the NS to form the detoxification system with the local toxin adsorption effect, and can be applied to the fields of biological medicines, medical auxiliary materials andthe like.